Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL577020 | 0.92 | TDP1 (0.61) | TDP1MAPK1HIF1ASLC6A2SLC6A3 | |
| SCHEMBL8649254 | 0.85 | TDP1 (0.57) | TDP1MAPK1HIF1ASLC6A2SLC6A3 | |
| SCHEMBL5655771 | 0.84 | TDP1 (0.52) | TDP1MAPK1HIF1ASLC6A2SLC6A3 | |
| SCHEMBL23083199 | 0.82 | CHRM2 (0.42) | LMNAALDH1A1CHRM2CHRM4CHRM1 | |
| SCHEMBL576103 | 0.81 | LMNA (0.55) | TDP1MAPK1HIF1ASLC6A2SLC6A3 | |
| SCHEMBL11310553 | 0.81 | TDP1 (0.53) | TDP1MAPK1HIF1ASLC6A2SLC6A3 | |
| SCHEMBL15863301 | 0.81 | TDP1 (0.53) | TDP1MAPK1HIF1ASLC6A2SLC6A3 | |
| Benzene SCHEMBL28861687 | 0.81 | LMNA (0.55) | TDP1MAPK1HIF1ASLC6A2SLC6A3 | |
| SCHEMBL2161673 | 0.81 | TDP1 (0.49) | TDP1MAPK1HIF1ASLC6A2SLC6A3 | |
| SCHEMBL15635611 | 0.80 | TDP1 (0.52) | TDP1MAPK1HIF1ASLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6156692-A | Ruthenium-containing catalyst composition for olefin metathesis | BP AMOCO CORPORATION (US) | 2000-12-05 | — | — | US | claimed |
| CN-100342037-C | Heat treatment method for a cold-rolled strip with an Ni and/or Co surface coating, sheet metal producible by said method and battery can producible by said method | HILLE & MUELLER GMBH (DE) | 2007-10-10 | — | — | CN | disclosed |
| US-7179911-B2 | coupling a silyl ester of (3S)-2,2-dimethyl-tetrahydro-2H-1,4-thiazine-3-carboxylic acid with 6,4-[4-(chlorosulfonyl)phenoxy]-2-butynyl acetate, hydrolyzing the silyl ester | WYETH (US) | 2007-02-20 | — | — | US | disclosed |
| WO-2005123705-A1 | METHOD FOR PREPARING HYDROXAMIC ACIDS | WYETH (US) | 2005-12-29 | — | — | WO | disclosed |
| US-20050272928-A1 | Method for preparing hydroxamic acids | WYETH (US) | 2005-12-08 | — | — | US | disclosed |
| CN-1636073-A | Heat treatment method for a cold-rolled strip with an Ni and/or Co surface coating, sheet metal producible by said method and battery can producible by said method | HILLE & MUELLER GMBH (DE) | 2005-07-06 | — | — | CN | disclosed |
| US-20030144319-A1 | Subtype-selective NMDA receptor ligands and the use thereof | BIGGE CHRISTOPHER F (US) | 2003-07-31 | — | — | US | disclosed |
| US-6534522-B2 | E.g.,N-((4-amino-3-nitrophenoxy)ethyl)-1,2,3,4-tetrahydro -isoquinoline; stroke; antiischemic agents; CNS trauma, hyperglycemic agents; surgery; neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis | WARNER-LAMBERT COMPANY | 2003-03-18 | — | — | US | disclosed |
| EP-0841988-B1 | A RUTHENIUM-BASED CATALYST COMPOSITION FOR OLEFIN METATHESIS | BP CORP NORTH AMERICA INC (US) | 2002-06-19 | — | — | EP | disclosed |
| US-20010051633-A1 | Subtype-selective NMDA receptor ligands and the use thereof | BIGGE CHRISTOPHER F (US) | 2001-12-13 | — | — | US | disclosed |
| US-6156692-A | Ruthenium-containing catalyst composition for olefin metathesis | BP AMOCO CORPORATION (US) | 2000-12-05 | — | — | US | disclosed |
| US-6143851-A | Process for preparation of addition products of difunctional telechelic polyolefins from cyclic olefins by olefin metathesis reaction | BP AMOCO CORPORATION (US) | 2000-11-07 | — | — | US | disclosed |
| US-6060570-A | Process for preparation of addition products of difunctional telechelic polyolefins from cyclic olefins by olefin metathesis reaction | BP AMOCO CORPORATION (US) | 2000-05-09 | — | — | US | disclosed |
| WO-1999022866-A1 | A RUTHENIUM-CONTAINING CATALYST SYSTEM FOR OLEFIN METATHESIS | BP AMOCO CORPORATION (US) | 1999-05-14 | — | — | WO | disclosed |
| EP-0857183-A1 | PROCESS FOR PREPARATION OF ADDITION PRODUCTS OF DIFUNCTIONAL TELECHELIC POLYOLEFINS FROM CYCLIC OLEFINS BY OLEFIN METATHESIS REACTION | AMOCO CORPORATION (US) | 1998-08-12 | — | — | EP | disclosed |
| EP-0841988-A1 | A RUTHENIUM-BASED CATALYST SYSTEM FOR OLEFIN METATHESIS | AMOCO CORPORATION (US) | 1998-05-20 | — | — | EP | disclosed |
| WO-1998006771-A1 | PROCESS FOR PREPARATION OF ADDITION PRODUCTS OF DIFUNCTIONAL TELECHELIC POLYOLEFINS FROM CYCLIC OLEFINS BY OLEFIN METATHESIS REACTION | AMOCO CORPORATION (US) | 1998-02-19 | — | — | WO | disclosed |
| WO-1997040934-A1 | A RUTHENIUM-BASED CATALYST SYSTEM FOR OLEFIN METATHESIS | AMOCO CORPORATION (US) | 1997-11-06 | — | — | WO | disclosed |
| US-5173113-A | Low-solvent or nonsolvent, quick drying | TOPEZ COMPANY (IO) | 1992-12-22 | — | — | US | disclosed |
| EP-0141873-A1 | Substituted diphenyl ether herbicides and process for use | GAF CORPORATION (US) | 1985-05-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272928-A1 | Method for preparing hydroxamic acids | H1-5, HDAC5, PGA5 | TDP1 3873/4885MAPK1 3177/4885HIF1A 133/4885 |
| US-20030144319-A1 | Subtype-selective NMDA receptor ligands and the use thereof | OPRK1, OPRD1, OPRL1 | TDP1 2512/4885MAPK1 1500/4885HIF1A 319/4885 |
| US-20010051633-A1 | Subtype-selective NMDA receptor ligands and the use thereof | OPRK1, OPRD1, OPRL1 | TDP1 2512/4885MAPK1 1500/4885HIF1A 319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.